Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Arix Bioscience plc Announces Changes to Board of Directors
Arix Bioscience plc Announces Changes to Board of Directors
Arix Bioscience plc Announces Changes to Board of Directors
eqs_en 
0 10.08.22
Interim Results for the Six Months Ended 30 June 2022
Interim Results for the Six Months Ended 30 June 2022
Interim Results for the Six Months Ended 30 June 2022
eqs_en 
0 10.08.22
Notice of Results & Investor Presentation
Notice of Results & Investor Presentation
Notice of Results & Investor Presentation
eqs_en 
0 03.08.22
Unaudited NAV for June 2022
Unaudited NAV for June 2022
Unaudited NAV for June 2022
eqs_en 
0 22.07.22
Notice of Investor Presentation
Notice of Investor Presentation
Notice of Investor Presentation
eqs_en 
0 22.06.22
Unaudited NAV for May 2022
Unaudited NAV for May 2022
Unaudited NAV for May 2022
eqs_en 
0 09.06.22
Result of Annual General Meeting 2022
Result of Annual General Meeting 2022
Result of Annual General Meeting 2022
eqs_en 
0 07.06.22
Unaudited NAV for April
Unaudited NAV for April
Unaudited NAV for April
eqs_en 
0 11.05.22
Clinical Development Update from Portfolio Company LogicBio
Clinical Development Update from Portfolio Company LogicBio
Clinical Development Update from Portfolio Company LogicBio
eqs_en 
0 09.05.22
Financial Results for the Year Ended 31 December 2021
Financial Results for the Year Ended 31 December 2021
Financial Results for the Year Ended 31 December 2021
eqs_en 
0 05.05.22
TR-1: Notification of major holdings
TR-1: Notification of major holdings
TR-1: Notification of major holdings
eqs_en 
0 04.05.22
Unaudited NAV and Notice of Financial Results
Unaudited NAV and Notice of Financial Results
Unaudited NAV and Notice of Financial Results
eqs_en 
0 29.04.22
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
eqs_en 
0 05.04.22
Corporate update from portfolio company Harpoon Therapeutics
Corporate update from portfolio company Harpoon Therapeutics
Corporate update from portfolio company Harpoon Therapeutics
eqs_en 
0 14.03.22
Total Voting Rights
Total Voting Rights
Total Voting Rights
eqs_en 
0 08.02.22
Arix Bioscience PLC: Clinical development update from portfolio company LogicBio
Arix Bioscience PLC: Clinical development update from portfolio company LogicBio
Arix Bioscience PLC: Clinical development update from portfolio company LogicBio
eqs_en 
0 02.02.22
Notification of Major Share Holding
Notification of Major Share Holding
Notification of Major Share Holding
eqs_en 
0 11.01.22
Arix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
Arix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
Arix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
eqs_en 
0 22.12.21
Arix Bioscience PLC: Director/PDMR Shareholdings
Arix Bioscience PLC: Director/PDMR Shareholdings
Arix Bioscience PLC: Director/PDMR Shareholdings
eqs_en 
0 17.12.21
Arix Bioscience PLC: Depixus raises €30.6M (£26.1 million) in Series A Financing
Arix Bioscience PLC: Depixus raises €30.6M (£26.1 million) in Series A Financing
Arix Bioscience PLC: Depixus raises €30.6M (£26.1 million) in Series A Financing
eqs_en 
0 15.12.21
Arix Bioscience PLC: Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
Arix Bioscience PLC: Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
Arix Bioscience PLC: Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
eqs_en 
0 13.12.21
Arix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
Arix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
Arix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
eqs_en 
0 13.12.21